Detalles de la búsqueda
1.
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
Cancer
; 127(17): 3194-3201, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33882143
2.
Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel.
Eur Urol
; 85(2): 171-176, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-37085425
3.
Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel.
Prostate Cancer Prostatic Dis
; 2024 Feb 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-38424319
4.
A Multicenter Phase II Trial of Ipilimumab and Nivolumab in Unresectable or Metastatic Metaplastic Breast Cancer: Cohort 36 of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART, SWOG S1609).
Clin Cancer Res
; 28(2): 271-278, 2022 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34716198
5.
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).
J Immunother Cancer
; 9(8)2021 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-34380663
6.
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors.
Clin Cancer Res
; 26(10): 2290-2296, 2020 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31969335
7.
Agreement Between Self-Reported and Confirmed Cancer Diagnoses in New York City Firefighters and EMS Workers, 2001-2011.
Public Health Rep
; 131(1): 153-9, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26843681
Resultados
1 -
7
de 7
1
Próxima >
>>